

Universitas Ngudi Waluyo
Program Studi Farmasi, Fakultas Kesehatan
Skripsi, Agustus 2022
Intan Meiliyanti
NIM: 052201038

EVALUASI PENGGUNAAN OBAT ANTIHIPERTENSI PADA PASIEN HIPERTENSI DI PUSKESMAS MEGANG KOTA LUBUKLINGGAU

ABSTRAK

Latar Belakang: Penyebab kematian nomor ketiga setelah stroke serta tuberculosis ialah hipertensi. Hipertensi merupakan penyakit kronis yang membutuhkan pengobatan dalam jangka waktu yang cukup panjang bahwa seumur hidup. Penelitian ini bertujuan untuk mengevaluasi penggunaan obat antihipertensi pada pasien hipertensi di Puskesmas Megang Kota Lubuklinggau.

Metode: Penelitian ini merupakan jenis penelitian non eksperimental. Penelitian ini dilakukan di Puskesmas Megang Lubuklinggau pada bulan Mei-Agustus 2022. Populasi pada penelitian ini adalah semua pasien hipertensi di Puskesmas Megang Lubuklinggau pada tahun 2021 dan berusia diatas 26 tahun sebanyak 210 orang. Pengambilan sampel pada penelitian ini menggunakan teknik *purposive sampling* sebanyak 68 orang. Pengolahan data melalui *editing, coding, tabulating*, dan *entry data*. Pada penelitian ini analisis data dilakukan secara deskriptif

Hasil: Penggunaan obat antihipertensi pada pasien hipertensi di Puskesmas Megang Kota Lubuklinggau tahun 2021 yaitu golongan *Calcium Channel Blocker* (amlodipine) sebanyak 55 pasien (80,88%), *Angiotensin Converting Enzyme Inhibitors* (captopril) sebanyak 3 pasien (4,41%). Dan kombinasi *Calcium Channel Blocker* (amlodipine) dan *Angiotensin Converting Enzyme Inhibitor* (Captopril) sebanyak 10 pasien (14,70%).

Simpulan: Evaluasi penggunaan obat antihipertensi pada pasien hipertensi di Puskesmas Megang Kota Lubuklinggau tahun 2021 yaitu ketepatan indikasi sebanyak 68 pasien (100%), ketepatan pemilihan obat sebanyak 68 pasien (100%), dan ketepatan dosis sebanyak 66 pasien (97,05%).

Kata Kunci: Antihipertensi, Evaluasi, Hipertensi, Obat

Ngudi Waluyo University
Pharmacy Study Program, Faculty of Health
Final Project, August 2022
Intan Meiliyanti
NIM: 052201038

EVALUATION OF THE USE OF ANTIHYPERTENSIVE DRUGS IN HYPERTENSIVE PATIENTS AT THE MEGANG HEALTH CENTER IN LUBUKLINGGAU CITY

ABSTRACT

Background: Hypertension was the third leading cause of death after stroke and tuberculosis. Hypertension is a chronic disease that requires treatment for a long period of time even for life. This study aims to evaluate the use of antihypertensive drugs in hypertensive patients at the Megang Health Center, Lubuklinggau City.

Method: This research was a type of non-experimental research. This study was conducted at the Megang Lubuklinggau Health Center in May-August 2022. The population in this study was all hypertension patients at the Megang Lubuklinggau Health Center in 2021 and were over 26 years old, as many as 210 people. Sampling in this study used purposive sampling techniques for 68 people. Data processing through editing, coding, tabulating, and data entry. In this study, data analysis was carried out descriptively.

Results: The use of antihypertensive drugs in hypertensive patients at the Megang Health Center in Lubuklinggau City in 2021, namely the Calcium Channel Blocker (amlodipine) group of 55 patients (80.88%), Angiotensin Converting Enzyme Inhibitors (captopril) as many as three patients (4.41%) and the combination of Calcium Channel Blockers (amlodipine) and Angiotensin Converting Enzyme Inhibitors (Captopril) in as many as ten patients (14.70%).

Conclusion: Evaluation of the use of antihypertensive drugs in hypertensive patients at the Megang Health Center in Lubuklinggau City in 2021, namely the accuracy of indications of 68 patients (100%), the accuracy of drug selection of as many as 68 patients (100%), and the accuracy of doses as many as 66 patients (97,05%).

Keywords: Antihypertensive, Evaluation, Hypertension, Medication